litlas
ログインアカウント作成

Howard A. Burris

1992–2025 年に発表

224
論文数
61,530
被引用数
115
h 指数
221
i10 指数

被引用数

Howard A. Burris の年別被引用数1964 年: 被引用 1 件1976 年: 被引用 1 件1993 年: 被引用 2 件1994 年: 被引用 12 件1995 年: 被引用 16 件1996 年: 被引用 23 件1997 年: 被引用 30 件1998 年: 被引用 32 件1999 年: 被引用 67 件2000 年: 被引用 64 件2001 年: 被引用 70 件2002 年: 被引用 87 件2003 年: 被引用 107 件2004 年: 被引用 98 件2005 年: 被引用 158 件2006 年: 被引用 155 件2007 年: 被引用 164 件2008 年: 被引用 246 件2009 年: 被引用 284 件2010 年: 被引用 313 件2011 年: 被引用 338 件2012 年: 被引用 396 件2013 年: 被引用 584 件2014 年: 被引用 632 件2015 年: 被引用 669 件2016 年: 被引用 710 件2017 年: 被引用 851 件2018 年: 被引用 855 件2019 年: 被引用 2,264 件2020 年: 被引用 2,310 件2021 年: 被引用 2,176 件2022 年: 被引用 1,839 件2023 年: 被引用 1,572 件2024 年: 被引用 2,362 件2025 年: 被引用 1,246 件2026 年: 被引用 34 件1965〜1975 年は被引用が無いため表示していません1977〜1992 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 8,012 件、この内訳の 27.6%中国: 引用元論文 2,967 件、この内訳の 10.2%イタリア: 引用元論文 1,749 件、この内訳の 6%イギリス: 引用元論文 1,652 件、この内訳の 5.7%ドイツ: 引用元論文 1,464 件、この内訳の 5%フランス: 引用元論文 1,384 件、この内訳の 4.8%スペイン: 引用元論文 1,113 件、この内訳の 3.8%日本: 引用元論文 925 件、この内訳の 3.2%カナダ: 引用元論文 916 件、この内訳の 3.2%オランダ: 引用元論文 812 件、この内訳の 2.8%オーストラリア: 引用元論文 760 件、この内訳の 2.6%スイス: 引用元論文 737 件、この内訳の 2.5%
0%27.6%その他 22.6%

機関

分野

  • Medicine64.2%
  • Biochemistry, Genetics and Molecular Biology26.9%
  • Immunology and Microbiology4%
  • Materials Science1.1%
  • Engineering0.7%
  • Neuroscience0.6%
  • その他2.5%

トピック

  • Cancer Immunotherapy and Biomarkers5.4%
  • HER2/EGFR in Cancer Research3.8%
  • Advanced Breast Cancer Therapies3%
  • Pancreatic and Hepatic Oncology Research2.9%
  • Colorectal Cancer Treatments and Studies2.5%
  • Cancer Genomics and Diagnostics2.4%
  • その他80%

共著者

全論文

検索で開く
  1. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

    著者: Do‐Youn Oh, Aiwu Ruth He, Shukui Qin, Li‐Tzong Chen, Takuji Okusaka, Arndt Vogel, Jin Won Kim, Thatthan Suksombooncharoen, Myung Ah Lee, Masayuki Kitano, Howard A. Burris, Mohamed Bouattour, Suebpong Tanasanvimon, Mairéad G. McNamara, Renata Zaucha, Antonio Avallone, Benjamin Tan, Juan Cundom, Choong‐kun Lee, Hidenori Takahashi, Masafumi Ikeda, Jen‐Shi Chen, Julie Wang, Mallory Makowsky, Nana Rokutanda, Philip He, John F. Kurland, Gordon Cohen, Juan W. Valle - NEJM Evidence 2022 被引用: 1,092

  2. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

    著者: Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer - The Lancet 2016 被引用: 3,714

  3. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

    著者: Paul M. Ridker, Jean MacFadyen, Tom Thurén, Brendan M Everett, Peter Libby, Robert J. Glynn, Paul M. Ridker, Alberto Lorenzatti, Henry Krum, George Varigos, Peter Siostrzonek, Peter Sinnaeve, Francisco Antônio Helfenstein Fonseca, José Carlos Nicolau, Nina Gotcheva, Jacques Genest, Yong Huo, Miguel Urina‐Triana, Davor Miličić, Renata Cífková, Riina Vettus, Wolfgang Köenig, S.D. Anker, Athanasios Manolis, Fernando Wyss, Tamás Forster, Axel F. Sigurðsson, Prem Pais, Alessandro Fucili, Hisao Ogawa, Hiroaki Shimokawa, Irina Veze, Birutė Petrauskienė, Leon Salvador, John J.P. Kastelein, Jan H. Cornel, Tor Ole Klemsdal, Félix Medina, Andrzej Budaj, L Vida-Simiti, Zhanna Kobalava, Petar Otašević, Daniel Pella, Mitja Lainščak, Ki‐Bae Seung, Patrick Commerford, Mikael Dellborg, Marc Y. Donath, Juey‐Jen Hwang, Hakan Kültürsay, Marcus Flather, Christie M. Ballantyne, Seth Bilazarian, William H. Chang, Cara East, Brendan Everett, Les B. Forgosh, Robert J. Glynn, Barry Harris, Peter Libby, M Ligueros, Tom Thurén, Erin A. Bohula, Bindu Charmarthi, Susan Cheng, Sherry Chou, Jacqueline Suk Danik, Graham T. McMahon, Bradley A. Maron, MingMing Ning, Benjamin A. Olenchock, Reena L. Pande, Todd S. Perlstein, Aruna D. Pradhan, Natalia S. Rost, Aneesh B. Singhal, Viviany R. Taqueti, Nancy Wei, Howard A. Burris, Angela Cioffi, Anne Marie Dalseg, Nilanjan Ghosh, Julie R. Gralow, Tina Mayer, Hope S. Rugo, Vance G. Fowler, Ajit P. Limaye, Sara E. Cosgrove, Donald P. Levine, Renato D. Lópes, John Scott, Tom Thurén, M Ligueros, Robert Hilkert, Georgia Tamesby, Carolyn Mickel, Brian Manning, Julian Woelcke, Monique Tan, S Manfreda ほか 19 名 - The Lancet 2017 被引用: 1,308

  4. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

    著者: Gabriel N. Hortobagyi, Salomon M. Stemmer, Howard A. Burris, Yoon-Sim Yap, Gabe S. Sonke, Lowell Hart, Mario Campone, Katarina Petrakova, Eric P. Winer, Wolfgang Janni, Pierfranco Conte, David A. Cameron, Fabrice André, Carlos L. Arteaga, Juan P. Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Joyce O’Shaughnessy - New England Journal of Medicine 2022 被引用: 713

  5. openalex_id:w4221085715

    著者: Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Lowell L. Hart, Mario Campone, Katarína Petráková, Eric P. Winer, Wolfgang Janni, PierFranco Conte, David Cameron, Fabrice André, Carlos L. Arteaga, Juan Pablo Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Joyce O’Shaughnessy 被引用: 579

  6. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    著者: Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, Katarína Petráková, Lowell L. Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva‐Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne Favret, Denise A. Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy - New England Journal of Medicine 2016 被引用: 2,009

  7. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

    著者: José Baselga, Mario Campone, Martine Piccart, Howard A. Burris, Hope S. Rugo, Tarek Sahmoud, Shinzaburo Noguchi, Michael Gnant, Kathleen I. Pritchard, Fabienne Lebrun, J. Thaddeus Beck, Yoshinori Ito, Denise A. Yardley, Ines Deleu, Alejandra Perez, Thomas Bachelot, Luc Vittori, Zhiying Xu, Pabak Mukhopadhyay, David Lebwohl, Gabriel N. Hortobágyi - New England Journal of Medicine 2011 被引用: 2,828

  8. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

    著者: Howard A. Burris, Malcolm J. Moore, John Sahl Andersen, M R Green, Mace L. Rothenberg, Manuel Modiano, M. Christine Cripps, Russell K. Portenoy, Anna Maria Storniolo, Peter G. Tarassoff, Ryan Nelson, F. Andrew Dorr, Connie Stephens, Daniel D. Von Hoff - Journal of Clinical Oncology 1997 被引用: 5,884

  9. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

    著者: John H. Strickler, Andrea Cercek, Salvatore Siena, Thierry André, Kimmie Ng, Eric Van Cutsem, Christina Wu, Andrew Scott Paulson, Joleen M. Hubbard, Andrew L. Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon Murtaza Kasi, Heinz‐Josef Lenz, Kristen K. Ciombor, Elena Élez, David L. Bajor, Chiara Cremolini, Federico Sanchez, Michael Stecher, Wentao Feng, Tanios Bekaii‐Saab, Eric Van Cutsem, Marc Peeters, Marc Van den Evnde, Thierry André, Christophe Borg, Matthieu Sarabi, François Ghiringhelli, Benoist Chibaudel, Salvatore Siena, Chiara Cremolini, Maria Giulia Zampino, Elena Élez, Susana R. Keranen, Ramón Salazar, Pilar Alfonso, John H. Strickler, Andrea Cercek, Kimmie Ng, Christina Wu, Andrew Scott Paulson, Joleen M. Hubbard, Andrew L. Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon Murtaza Kasi, Heinz‐Josef Lenz, Kristen K. Ciombor, David L. Bajor, Tanios Bekaii‐Saab, Olumide B. Gbolahan, Patrick M. Boland, Daniel Berg, Federico Sanchez, Timothy F. Goggins, Federico Sanchez, Howard A. Burris, Johanna C. Bendell, Darryl Outlaw, Isaac Tafur, Ardaman Shergill, Daniel V.T. Catenacci, Jun Gong, Ignacio Garrido‐Laguna, Gene Grant Finley, Benjamin A. Weinberg, Anthony F. Shields, Philip Philip, Anita Turk, Anthony Nguyen, Fadi Braiteh, Vijay Patel, William Harwin, Ian Anderson, Ajay Kundra, Christopher S. Chen, James M. Ford, Madappa N. Kundranda, Danny Nguyen, Suresh Ratnam, Donald Richards, Sujatha Nallapareddy, Sridhar Beeram, Scott McKenney, Spencer H. Shao, Scott McKenney, Spencer H. Shao - The Lancet Oncology 2023 被引用: 245

  10. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

    著者: Funda Meric‐Bernstam, Herbert I. Hurwitz, Kanwal Raghav, Robert R. McWilliams, Marwan Fakih, Ari M. Vanderwalde, Charles Swanton, Razelle Kurzrock, Howard A. Burris, Christopher J. Sweeney, Ron Bose, David R. Spigel, Mary Beattie, Steven Blotner, Alyssa Stone, Katja Schulze, Vaikunth Cuchelkar, John D. Hainsworth - The Lancet Oncology 2019 被引用: 564

  11. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

    著者: Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham Pant, Arthur E. Frankel, Peter Schmid, Kathleen N. Moore, William McCulloch, Katharine Grimmer, Marie O’Farrell, George Kemble, Howard A. Burris - EClinicalMedicine 2021 被引用: 275

  12. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

    著者: Milind Javle, Mitesh J. Borad, Nilofer S. Azad, Razelle Kurzrock, Ghassan K. Abou‐Alfa, Ben George, John D. Hainsworth, Funda Meric‐Bernstam, Charles Swanton, Christopher J. Sweeney, Claire F. Friedman, Ron Bose, David R. Spigel, Yong Wang, Jonathan Levy, Katja Schulze, Vaikunth Cuchelkar, Arisha Patel, Howard A. Burris - The Lancet Oncology 2021 被引用: 406

  13. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

    著者: Xīn Gào, Howard A. Burris, Jacqueline Vuky, Robert Dreicer, Oliver Sartor, Cora N. Sternberg, Ivor Percent, Maha Hussain, Arash Rezazadeh Kalebasty, John Shen, Elisabeth I. Heath, Guillermo Abesada‐Terk, Sunil Gandhi, Meredith McKean, Haolan Lu, Elmer Berghorn, Richard Gedrich, S. Debbie Chirnomas, Nicholas J. Vogelzang, Daniel P. Petrylak - Journal of Clinical Oncology 2022 被引用: 186

  14. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    著者: Thomas Powles, Joseph P. Eder, Gregg Fine, Fadi S. Braiteh, Yohann Loriot, Cristina Cruz, Joaquim Bellmunt, Howard A. Burris, Daniel P. Petrylak, Siew-leng Melinda Teng, Xiaodong Shen, Zachary Boyd, Priti S. Hegde, Daniel S. Chen, Nicholas J. Vogelzang - Nature 2014 被引用: 2,430

  15. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    著者: Keith T. Flaherty, J. Infante, Adil Daud, René González, Richard Kefford, Jeffrey A. Sosman, Omid Hamid, Lynn M. Schuchter, Jonathan Cebon, Nageatte Ibrahim, Ragini R. Kudchadkar, Howard A. Burris, Gerald S. Falchook, Alain P. Algazi, Karl D. Lewis, Georgina V. Long, Igor Puzanov, Peter F. Lebowitz, Ajay P. Singh, Shonda M Little, Peng Sun, Alicia J. Allred, Danièle Ouellet, Kevin B. Kim, Kiran Patel, Jeffrey S. Weber - New England Journal of Medicine 2012 被引用: 2,798

  16. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

    著者: Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer, Neal Ready, Daniel Morgensztern, Bonnie S. Glisson, Lauren A. Byers, Melissa L. Johnson, Howard A. Burris, Francisco Robert, Tae Hyung Han, Sheila Bheddah, Noah Theiss, Sky Watson, Deepan Mathur, Bharathi Vennapusa, Hany Zayed, Satwant Lally, Donald K. Strickland, Ramaswamy Govindan, Scott J. Dylla, Stanford L. Peng, David R. Spigel - The Lancet Oncology 2016 被引用: 553

  17. Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma

    著者: Ingo K. Mellinghoff, Benjamin M. Ellingson, Mehdi Touat, Elizabeth A. Maher, Macarena I. de la Fuente, Matthias Holdhoff, Gregory M. Coté, Howard A. Burris, Filip Jankú, Robert J. Young, Raymond Y. Huang, Liewen Jiang, Sung Choe, Bin Fan, Katharine Yen, Min Lu, Chris Bowden, Lori Steelman, Shuchi S. Pandya, Timothy F. Cloughesy, Patrick Y. Wen - Journal of Clinical Oncology 2020 被引用: 307

  18. Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

    著者: Ingo K. Mellinghoff, Marta Peñas-Prado, Katherine B. Peters, Howard A. Burris, Elizabeth A. Maher, Filip Jankú, Gregory M. Coté, Macarena I. de la Fuente, Jennifer Clarke, Benjamin M. Ellingson, Saewon Chun, Robert J. Young, Hua Liu, Sung Choe, Min Lu, Kha Le, Islam Hassan, Lori Steelman, Shuchi S. Pandya, Timothy F. Cloughesy, Patrick Y. Wen - Clinical Cancer Research 2021 被引用: 259

  19. Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

    著者: Dejan Juric, Jordi Rodón, Josep Tabernero, Filip Jankú, Howard A. Burris, Jan H.M. Schellens, Mark R. Middleton, Jordan Berlin, Martin Schüler, Marta Gil-Martín, Hope S. Rugo, Ruth Seggewiß-Bernhardt, Alan Huang, Douglas Bootle, David Demanse, Lars Blumenstein, Christina Coughlin, Cornelia Quadt, José Baselga - Journal of Clinical Oncology 2018 被引用: 439

  20. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

    著者: Do‐Youn Oh, Aiwu Ruth He, Mohamed Bouattour, Takuji Okusaka, Shukui Qin, Li‐Tzong Chen, Masayuki Kitano, Choong‐kun Lee, Jin Won Kim, Ming‐Huang Chen, Thatthan Suksombooncharoen, Masafumi Ikeda, Myung Ah Lee, Jen‐Shi Chen, Piotr Potemski, Howard A. Burris, Vikas Ostwal, Suebpong Tanasanvimon, Chigusa Morizane, Renata Zaucha, Mairéad G. McNamara, Antonio Avallone, Juan E Cundom, В. В. Бредер, Benjamin Tan, Satoshi Shimizu, David Tougeron, Ludovic Evesque, Mila Petrova, David B. Zhen, Roopinder Gillmore, Vineet Gupta, Farshid Dayyani, Joon Oh Park, Gary L. Buchschacher, Felipe Rey, Hyosung Kim, Julie Wang, Claire Morgan, Nana Rokutanda, Magdalena Żotkiewicz, Arndt Vogel, Juan W. Valle - ˜The œLancet. Gastroenterology & hepatology 2024 被引用: 254

  21. First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    著者: Josep Tabernero, Geoffrey I. Shapiro, Patricia LoRusso, Andrés Cervantes, Gary K. Schwartz, Glen J. Weiss, Luis Paz‐Ares, Daniel C. Cho, Jeffrey R. Infante, María Alsina, Mrinal M. Gounder, Rick Falzone, Jamie Harrop, Amy C. Seila White, Iva Toudjarska, David Bumcrot, Rachel Meyers, Gregory Hinkle, Nenad Svrzikapa, Renta Hutabarat, Valerie A. Clausen, Jeffrey Cehelsky, Saraswathy V. Nochur, Christina Gamba‐Vitalo, Akshay Vaishnaw, Dinah W.Y. Sah, Jared Gollob, Howard A. Burris - Cancer Discovery 2013 被引用: 699

  22. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

    著者: John D. Hainsworth, Funda Meric‐Bernstam, Charles Swanton, Herbert I. Hurwitz, David R. Spigel, Christopher J. Sweeney, Howard A. Burris, Ron Bose, Bongin Yoo, Alisha Stein, Mary Beattie, Razelle Kurzrock - Journal of Clinical Oncology 2018 被引用: 505

  23. Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

    著者: Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja, Charles L. Vogel, R. Borson, Steven Limentani, Elizabeth Tan-Chiu, Ian E. Krop, Richard A. Michaelson, Sandhya Girish, Lukas C. Amler, Maoxia Zheng, Yu-Waye Chu, Barbara Klencke, Joyce O’Shaughnessy - Journal of Clinical Oncology 2010 被引用: 764

  24. First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).

    著者: Daniel P. Petrylak, Xīn Gào, Nicholas J. Vogelzang, Mary Harlow Garfield, I Taylor, Marcia Dougan Moore, Ronald A. Peck, Howard A. Burris - Journal of Clinical Oncology 2020 被引用: 165